Hos gravide rotter resulterede systemisk indgivelse af travopost i doser på mere end 200 gange den kliniske dosis gennem organogenese- perioden i et forøget antal misdannelser.
In pregnant rat, systemic administration of travoprost at doses more than 200 times the clinical dose during the period of organogenesis resulted in an increased incidence of malformations.